Breakthrough Clinical Trial Reveals New Hope for Early Morning Shift Workers Battling Severe Fatigue

The modern economy runs on a 24-hour cycle, yet human biology remains firmly tethered to the sun. While much of the cultural and medical conversation surrounding occupational fatigue has historically focused on overnight workers—such as nurses pulling grueling night shifts, long-haul truckers driving through the dead of night, and factory workers on the graveyard shift—a far larger segment of the workforce faces an equally punishing schedule: the early morning shift. Millions of individuals begin their professional days well before dawn, launching into high-stakes responsibilities while the rest of the world is still fast asleep.

Despite the massive scale of this workforce, a glaring blind spot has persisted in clinical research. Until recently, virtually no randomized clinical trials had evaluated targeted medical interventions for individuals working early morning shifts, leaving a vast population of exhausted laborers to fend for themselves against a formidable biological barrier. However, a landmark clinical trial led by researchers at Mass General Brigham has shattered this long-standing research gap. Published in the prestigious journal NEJM Evidence, the study demonstrates that the wake-promoting pharmaceutical agent solriamfetol (marketed as Sunosi) can significantly improve alertness, job performance, and daily functioning in early morning shift workers diagnosed with shift work disorder.

The findings offer a profound paradigm shift for occupational health, illuminating the hidden biological toll paid by millions of essential workers and pointing toward a future where modern medicine can help bridge the dangerous gap between human physiology and economic demand.

Understanding the Hidden Epidemic of Early Morning Fatigue

To fully grasp the significance of the Mass General Brigham trial, one must examine the sheer scope of modern shift work. Approximately one in four workers in industrialized nations operates outside the traditional Monday-through-Friday, 9-to-5 schedule. Within this massive demographic, early morning shifts—typically requiring employees to wake and report to work between 3:00 a.m. and 7:00 a.m.—represent the single most common category of shift scheduling.

Yet, a dangerous misconception often permeates this group. Many individuals who begin their days at 4:00 or 5:00 in the morning do not consciously identify as "shift workers." Instead, they view their routines simply as starting the day earlier than usual, perhaps to beat traffic, meet production quotas, or accommodate operational demands. Consequently, they fail to recognize that their exhaustion is not merely a lack of willpower or poor sleep hygiene, but rather a clinical condition known as shift work disorder (SWD).

SWD is characterized by chronic or recurrent patterns of sleep disruption that result from working non-traditional hours, leading directly to symptoms of excessive daytime sleepiness or insomnia. For early morning workers, the struggle is compounded by what sleep scientists describe as a biological "double burden."

"People who start work between 3 a.m. and 7 a.m. are waking up at a time when the brain is biologically programmed to sleep," explains Dr. Kirsi-Marja Zitting, an investigator with the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine and first author of the study. "That makes staying alert extraordinarily difficult, even when they are highly motivated. They are often dealing with a double burden—excessive sleepiness during work hours and difficulty sleeping enough when they have the chance to rest."

The human circadian pacemaker, housed within the suprachiasmatic nucleus of the hypothalamus, dictates a daily rhythm of alertness and sleepiness aligned with natural light-dark cycles. When an individual attempts to override this internal clock by initiating high-level cognitive or physical activity during the circadian nadir—the biological night—cognitive performance plummets. Reaction times slow, memory retention degrades, and executive functioning falters, creating an environment ripe for catastrophic errors.

The Ripple Effects: Health, Safety, and Economic Implications

The societal costs of untreated shift work disorder extend far beyond individual exhaustion. Decades of epidemiological research have linked chronic circadian disruption and sleep deprivation to a myriad of severe health consequences, including cardiovascular disease, metabolic disorders, type 2 diabetes, obesity, and certain forms of cancer.

However, the immediate occupational and public safety hazards are often the most alarming. Sleep-deprived workers exhibit deficits comparable to, or even exceeding, legal intoxication. In high-stakes environments—such as healthcare, public transportation, aviation, and heavy manufacturing—these cognitive lapses can prove fatal. Workers suffering from unmanaged SWD experience significantly higher rates of motor vehicle accidents during their commutes home, increased frequencies of near-misses on the job, and a greater incidence of severe workplace injuries.

Dr. Charles A. Czeisler, chief and senior physician of the Division of Sleep and Circadian Medicine at Mass General Brigham and senior author of the trial, emphasizes the urgency of addressing this crisis. "Shift workers are essential to how our society functions, yet they often pay a hidden biological cost," Dr. Czeisler states. "This study shows we can do better for them."

Historically, medical options for managing SWD have been severely limited. While wake-promoting medications such as modafinil have been prescribed off-label or approved for overnight workers, their pharmacological profiles are not always ideal for early morning schedules. Many traditional stimulants possess half-lives that can interfere with the fragmented sleep schedules these workers desperately need when they finally return home to rest, creating a vicious cycle of chemical stimulation followed by forced, poor-quality sleep.

The Pharmacology of Solriamfetol: A Promising Candidate

Enter solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor (DNRI) previously approved by regulatory agencies for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea (OSA) and narcolepsy.

Before the Mass General Brigham trial, researchers identified solriamfetol as a uniquely promising candidate for shift work disorder due to its balanced pharmacological profile. Unlike some older stimulants that cause jagged peaks and valleys in alertness or linger excessively in the system, solriamfetol provides sustained wake-promoting efficacy over extended periods without wreaking total havoc on subsequent sleep architecture.

Because early morning workers need maximum alertness during the dawn hours—when their biological clocks are demanding deep sleep—but also require the ability to wind down and sleep during daylight hours, a medication with predictable and manageable pharmacokinetics is vital. The clinical trial was designed precisely to test whether solriamfetol could successfully navigate this delicate physiological tightrope.

Inside the Clinical Trial: Methodology and Rigorous Design

To evaluate the drug’s safety and efficacy, the research team at Mass General Brigham designed a robust, randomized, double-blind, placebo-controlled clinical trial. The study enrolled 78 participants, all of whom were rigorously screened, diagnosed with shift work disorder, and identified as early morning shift workers.

Over a four-week intervention period, participants were randomly assigned to receive either daily doses of solriamfetol or an inactive placebo on their scheduled workdays. The trial utilized sophisticated testing environments to measure alertness under standardized, low-stimulation conditions that directly mirrored the physiological challenges of their typical early-morning work schedules.

In addition to objective assessments of sustained attention and wakefulness, researchers incorporated comprehensive subjective measures. Participants maintained detailed daily functional diaries and engaged in regular clinical evaluations with sleep specialists to report on their perceived ability to manage job tasks, cognitive clarity, and overall quality of life.

The Results: Clear Improvements in Alertness and Functioning

The four-week trial yielded striking and clinically meaningful results. Participants who received solriamfetol demonstrated a statistically significant reduction in excessive daytime sleepiness compared to the placebo group. More importantly, they exhibited a vastly improved ability to sustain wakefulness and attention throughout simulated work hours that coincided with their biological night.

Both the patients and their supervising clinicians noted substantial enhancements in overall daily functioning. Workers reported greater mental clarity, improved performance on job-related tasks, and a heightened capacity to navigate the rigorous demands of their professions without succumbing to debilitating fatigue.

"The improvement we saw is clinically meaningful," Dr. Czeisler observed following the publication of the findings. "These workers were able to stay awake and alert throughout a full eight-hour shift, which has real implications for performance, safety, and quality of life."

Crucially, the medication was well-tolerated among the otherwise healthy adult cohort during the four-week study window, reinforcing its potential as a viable therapeutic tool for a demographic that has long been ignored by pharmaceutical developers and clinical researchers alike.

Looking Ahead: Future Research and Regulatory Horizons

While the results of the Mass General Brigham trial represent a monumental leap forward for occupational medicine, the research team is careful to outline the limitations of the study and the necessary next steps.

The trial was deliberately constrained to a four-week duration and focused exclusively on otherwise healthy adults. Consequently, additional research is required to evaluate the long-term safety, efficacy, and potential tolerance development associated with chronic, multi-year use of solriamfetol in diverse populations, including workers with underlying medical conditions or advanced age.

Building upon the success of this initial study, Dr. Czeisler, Dr. Zitting, and their colleagues are already expanding their investigative scope. The research team is actively enrolling participants for a follow-up clinical trial designed to study the efficacy of solriamfetol in overnight shift workers. Data from this subsequent trial could provide the comprehensive evidentiary foundation required to support broader regulatory approvals specifically for the treatment of shift work disorder across all scheduling paradigms.

The trial was made possible through collaborative funding and support from Jazz Pharmaceuticals, Axsome Therapeutics, and the Brigham and Women’s Hospital Center for Clinical Investigation (registered under clinicaltrials.gov identifier NCT04788953). Alongside Drs. Zitting and Czeisler, the research team included a distinguished roster of Mass General Brigham investigators: Katherine R. Gilmore, Brandon J. Lockyer, Wei Wang, Nicolas C. Issa, Stuart F. Quan, Jonathan S. Williams, Jeanne F. Duffy, and independent researcher Eileen B. Leary.

Broader Implications for Employers and Public Policy

As society continues to accelerate toward a hyper-connected, round-the-clock economic model, the health and safety of shift workers can no longer remain an afterthought. The findings from Mass General Brigham serve as a wake-up call for employers, occupational health organizations, and policymakers alike.

For decades, addressing shift work fatigue has relied primarily on behavioral adjustments—such as strategic napping, caffeine consumption, and light therapy—which, while helpful, often prove insufficient against the immense power of human circadian biology. The validation of a targeted pharmacological intervention like solriamfetol opens up an entirely new dimension of workplace wellness and safety management.

However, medical professionals caution that drugs should not be viewed as a silver bullet designed to replace systemic reforms in scheduling practices. Experts emphasize that employers must continue to optimize shift schedules, limit consecutive grueling shifts, and provide adequate recovery periods to protect worker health. When combined with smart scheduling and proactive occupational health policies, targeted therapeutics like solriamfetol could drastically reduce workplace accidents, safeguard employee longevity, and elevate the standard of living for the millions of individuals who wake up in the dark to keep society moving forward.